02137.HK
Brii Biosciences Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.98
+1.03%Year over year
Reported trailing growth
- Revenue
- -44.8%
- EBITDA
- +25.3%
- EBIT
- +24.5%
- EPS
- +53.2%
- Free cash flow
- +30.6%
- Operating cash flow
- +33.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -29.5%
- EBITDA
- +25.7%
- EBIT
- +25.9%
- Net income
- +57.3%
- EPS
- +57.1%
- Free cash flow
- +23.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026